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 2 
Abstract  3 
The prevalence of co-morbidities in older people gives rise to the number of prescribed 4 
medicine increasing the complexity of medicine management.  Multi-compartment 5 
compliance aids and dispensing systems have the potential to organise the daily life of an 6 
older person. Various features of currently available compliance aids (such as multi-7 
compartment design or an automated reminder function) have proved successful in assisting 8 
older patients to take their medication.  This in turn enables them to manage their own often 9 
complex drug regimens.  Further investigations and collaborations between healthcare 10 
professionals, patients and carers are required for validated and effective use of compliance 11 
aids.  12 
 13 
 14 
Introduction 15 
The proportion of the population above the age of sixty is growing (NIH, 2011) as a result of 16 
medical advances and the resulting increase in life expectancy.  This combination of factors 17 
is placing pressure on the healthcare professionals and the pharmaceutical industry to meet 18 
this increased demand for healthcare services and improved patient related outcomes. 19 
Studies have shown that older individuals use large numbers of medicines (Ferrini and 20 
Ferrini, 2000) and are at risk of polypharmacy (Wilson et al,, 2007).  The prevalence of 21 
polypharmacy is high (Haider et al., 2009) leading to potentially inappropriate drug use and 22 
non-adherence in geriatric population.  23 
 24 
Although multiple definitions for polypharmacy have been identified in the literature (Fulton et 25 
al., 2005; Jorgenson et al., 2001; Veehof et al., 2000), the most commonly used definition is 26 
the concurrent use of ﬁve or more drugs (Haider et al., 2009).  Concerns regarding 27 
polypharmacy have been raised (Compton, 2013), particularly due to related issues of 28 
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medicine self-administration, medicine administration timing, supply of medicines and most 29 
importantly patient adherence to medicine taking.  30 
 31 
Adherence as defined by other researchers (Nunes et al., 2009) is the extent to which a 32 
patient’s behaviour matches the agreed recommendations of the prescriber. Non-adherence 33 
is a common occurrence with older patients and is characterised in several ways including 34 
hesitancy towards initiating medication taking, skipping doses, dose adjusting, using 35 
unsuitable routes of administration and over-adherence (Oboh, 2011). Unfortunately, these 36 
behaviours are not commonly disclosed to healthcare professionals more specifically the 37 
prescriber.  38 
 39 
The complex medication regimens of older individuals require strategies to assist with 40 
medicine self-management. To overcome medicine management issues related to 41 
polypharmacy, healthcare professionals such as general practitioners (GPs) and 42 
pharmacists, often recommend or assist with the preparation and supply of multi-43 
compartment compliance aids (MCA) (automated and non-automated) for solid dosage 44 
forms.  The community pharmacy contract in England and Wales recommends assessing 45 
and providing MCAs, to individuals who fall within the protection of the Disability 46 
Discrimination Act 1995 (DDA) and require assistance with medicine taking. 47 
 48 
Electronic health technologies have shown great potential to improve patient quality of life as 49 
observed in the outcome of the Automated Pill Dispenser Project which was conducted in 50 
the West Midlands region in March 2012.   The automated pill dispenser (APD) used in this 51 
study comprises of a movable carousel with divisions containing the precise amount of oral 52 
medicine to be taken at a specific time. An auditory alarm reminds the patient to take the 53 
medicine and an electronic alert provides feedback to carers.   54 
 55 
3 
 
A digital wireless personal information system developed by Proteus Biomedical has recently 56 
become available in the United Kingdom (UK).  This system consists of a sensor-enabled 57 
tablet and sensor patch which detects each time the patient takes their medicine (Lancet, 58 
2012). This system is also able to notify the caregiver and/or healthcare professional about 59 
the patient’s daily activities as well as their medicine management.  Whilst electronic 60 
dispensing systems have the potential to improve medicine management for older 61 
individuals, further work is required to ensure their designs promote patient adherence. 62 
 63 
As the population ages, it is likely that older individuals will receive solid, orally administered 64 
medicines in MCAs (Adams et al., 2013). Recent observations (Orlu-Gul et al., 2014) 65 
identified that some community pharmacists do not find the currently available MCAs 66 
`pharmacist friendly` in terms of ease of dispensing and accuracy checking.  To assist 67 
pharmacists in their delivery of efficient and effective medicine services, MCAs should be 68 
designed to support this and should be compatible with current dispensing practices whilst 69 
maintaining the stability of the repackaged medicines once removed from their original 70 
packaging. An evaluation of commonly used adherence aids and future considerations 71 
concerning pharmacists in particular community pharmacists involved in the dispensing of 72 
MCAs are presented in this paper.  73 
 74 
Defining MCAs 75 
 ‘Medicine compliance aids’ including MCAs and monitored dosage systems (MDS) are 76 
devices capable of enhancing patient adherence. There are numerous aids which have been 77 
designed to improve patient adherence however, there is limited clinical evidence to 78 
demonstrate MCA increase the compliance (Fowells et al., 2013). Most MCAs comprise of 79 
compartments which correspond to a single medicine administration time and all of an 80 
individual’s solid, orally administered medicines prescribed for that time are dispensed into 81 
that compartment by pharmacy staff.  Where frequency of administration does not exceed 82 
four times a day, a 28 compartment MCA provides a seven day dosing regimen for their 83 
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medicines.  MCAs can be purchased by individuals or supplied by pharmacists and can be 84 
disposable or reusable. These devices can also assist with managing medicines when a 85 
formal or informal carer is involved.  86 
 87 
Medicines are packed into MCAs by removing them from original medicine containers and 88 
organising them into the MCA.  As this process occurs between pharmacy medicine 89 
dispensing and administration, correct MCA preparation is a prerequisite for patient medicine 90 
adherence.  National institutional regulations outline those responsible for preparing MCAs in 91 
healthcare settings; in most cases the responsibility falls to nursing staff or pharmacists and 92 
other pharmacy staff (Nunney et al., 2001). As removing medicines from their original 93 
container and packing them into a MCA invalidates the manufacturer’s stability guarantee, 94 
the healthcare professional should make an informed judgement as to the effect on the 95 
quality and safety of this repackaging process (Haywood et al., 2011). Original medicine 96 
containers provide medicine protection to appropriate pharmacopoeia and quality standards 97 
for a variety of criteria including prevention of moisture and light exposure.  However, a 98 
compliance aid cannot guarantee the same level of protection (Donyai et al., 2010).  99 
 100 
A unanimous set of aims for the general use of MCAs have been identified (Wick, 2011):  101 
 to provide easily accessible medicine storage;  102 
 to reduce the complexity of medicine adherence;  103 
 to minimise errors associated with administration incorrect doses at incorrect times;  104 
 to act as a memory aid; 105 
 to show whether medicine doses have been administered or taken.  106 
 107 
The Royal Pharmaceutical Society (RPS) (Fowells et al., 2013) suggests that the patient or 108 
carer should be involved in the decision making process and educated on the advantages, 109 
uncertainties and risks of MCA use. Assessment for MCA use should include consideration 110 
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of the patient characteristics, benefit versus risk of supplying medicines in a MCA and the 111 
equality and disability discrimination legislation during the assessment (PSNC, 2013).  112 
 113 
Comparison of MCAs 114 
While MCAs can decrease the complexity associated with polypharmacy (George et al., 115 
2008), there is no universal awareness of the most effective and easy-to-use compliance 116 
aid, additionally, no single MCA is suitable for all individuals.  Moreover the information 117 
about the cost-effectiveness of various compliance aids is limited. In the UK,  Boots MDS®, 118 
Nomad®, Dossette®, Medidos® and 7-day Venalink® systems are commonly used (Oboh, 119 
2011). 120 
A Healthcare Compliance Packaging Council of Europe has been developed, to represent 121 
the pharmaceutical industry, the packaging industry and representatives of patient 122 
organisations in Europe, with the aim of advising the healthcare sector on how to improve 123 
patient adherence with packaging solutions (Council HCP, 2014). This Council has been at 124 
the forefront of enhancing devices including: 125 
 multi-dose dispensing systems;  126 
 alarmed pill boxes; 127 
 specific medical alarms; and 128 
 pictograms to act as instruction and reminders.  129 
In addition, other equally effective yet simpler methods exist (Oboh, 2013) including  130 
 Reminder systems such as timed alarms, telephone reminders, fridge stickers, and 131 
positioning medication in visible places. 132 
 Automatically generated reminder charts are practical and cost effective  133 
 Simplifying drug regimens and dispensing into appropriate containers 134 
 Explaining about the personalised importance of their medicines  135 
 Repeat dispensing, prescription collection and medicines delivery services 136 
 Patients keeping records of their medicine taking and monitoring their conditions 137 
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 Non-childproof tops, large labels, large prints, medicines administration records 138 
(MAR) sheets (Gujral et al., 2013).  139 
 140 
Current challenges related to MCAs 141 
Although MCAs are commonly used, their effectiveness has not been proven in the literature 142 
(Nunney et al., 2001; Rivers, 1992; McGrow et al., 2000). There is on-going debate about 143 
the overreliance of MCAs and there is insufficient evidence to support its benefit in improving 144 
medicine adherence. The analysis of the cost-consequence of a pharmacist-led medication 145 
review service, which included the provision of MCAs, showed that the mean cost saving 146 
was £307 per patient after an intervention was implemented for six months. The resulting 147 
increase in medicine adherence did not lead to a significant change in quality of life 148 
(Desborough et al., 2012).  149 
 150 
An important issue associated with MCA use is the stability of medicines once they are 151 
removed from their original containers and packed into the MCA. The Royal Pharmaceutical 152 
Society advises that medicines should not be stored in a MCA for longer than eight weeks 153 
(RPS, 2013) and have noted that the lack of sufficient stability data to support the 154 
repackaging of medicines into MCAs is an important issue when considering the usefulness 155 
of MCAs. Research conducted to investigate stability has shown little changes to drugs such 156 
as paracetamol after light and temperature alterations within a six week window (Haywood et 157 
al., 2006). However there is a handling process allowing for ruptured seal errors changing 158 
the previous stable conditions before even reaching the patient (Haywood et al., 2006). 159 
Possible interactions between medicines packed within the same MCA compartment is 160 
another consideration. For example, atenolol and aspirin have shown changes to hardness 161 
when packed together, potentially affected their quality. To assist with preserving medicine 162 
stability, time associated with packing medicines should be limited and medicines should be 163 
removed from the original container just prior to packing within a MCA. MCAs should be 164 
sealed and exposure to heat sealing should be limited (Haywood et al., 2011).  165 
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 166 
MCAs are also associated with a risk of secondary dispensing errors that may go undetected 167 
(Oboh, 2013; Alldred et al., 2009). This raises the issue of the safety of MCAs. As the usage 168 
increases there is a strain placed on the workload of both GPs and community pharmacists 169 
(Oboh, 2011). MCAs administered by carers also have the potential to lead to errors if 170 
medicine identification is difficult and if the MCA fails to accommodate dose and medicine 171 
descriptions.  172 
 173 
MCAs have limited available space for each medicine dose, are not airtight and offer less 174 
moisture and light protection than original medicine containers. There is a shortage of short-175 
term stability data for the transfer of medicines into MCAs (Mylrea et al., 2013).  176 
 177 
 178 
Current considerations on MCAs 179 
GPs should promote self-administration where possible in older individuals to facilitate 180 
autonomy in medicine taking. A patient-centred approach to medicine adherence 181 
intervention would involve liaising with local pharmacists and care home staff to understand 182 
reasons for non-adherence, and the suitability of MCAs for individual patients. 183 
 184 
Pharmacists should use their expertise to tailor medicine delivery in the best way to older 185 
individuals through tools such as Medicine Use Review (MUR). MUR is one of the four 186 
advanced services within the NHS community pharmacy contract and assesses whether 187 
individuals are receiving the best possible outcomes from their medicines and can identify 188 
problems associated with medicine taking, such as side-effects, medicine accessibility, 189 
adherence issues (Oboh, 2013). This is only a compulsory procedure in the case of a patient 190 
who qualifies under the DDA (PSNC, 2013). Pharmacist-led interventions for older patients 191 
can be resource intensive which makes their cost-benefit reasoning questionable (Banning 192 
et al., 2009). There is need for a formal and objective approach to making the decision to 193 
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use an MCA. The RPS states `Although MCA may be of value to help some patients with 194 
problems managing their medicines and maintaining independent healthy living, they are not 195 
the only intervention for all patients and many alternative interventions are available. 196 
Pharmacists need to be empowered to work with patients to find the best intervention that 197 
helps people use their medicines` (RPS, 2013).  198 
 199 
Blister pack MCAs are commonly used by UK community pharmacists, potentially due to low 200 
costs and ease of use when faced with manual dexterity issues. However, it is limited to four 201 
possible times of medicine administration (morning, lunch, evening and night) and may not 202 
easily accommodate medicines designed to be administered outside of these. Examples 203 
include alendronate for osteoporosis which should be taken first thing in the morning or 204 
medicines for Parkinson’s disease which requires multiple daily dosing. Although there is a 205 
strong argument to suggest that adherence aids may not be cost-effective (Mahtani et al. 206 
2011), it is necessary to weigh up the advantages and disadvantages of their use, including 207 
the cost of a device compared to the cost of hospital readmission due to poor adherence. 208 
Another issue is how some care companies refuse to administer from MCAs and others help 209 
prompt them. It is expected to be the same policy across all care homes in the UK. 210 
 211 
Many older individuals, particularly those who experience polypharmacy and co-morbidities 212 
will be assisted by carer. There is said to be a large support base for the use of MCAs from 213 
care homes due to their convenience for the staff and stock control. However there is also 214 
concern about providing inadequate information on pharmacological effects and therefore 215 
patient responses to their regime. Carers are allowed to prompt the patient to take a dose for 216 
example which essentially removes the need for an MCA and also educates them of the 217 
patient’s personalised routine making it less like a chore. Some carers argue that the need 218 
for an MCA on their behalf is for protection and accuracy of medication administration due to 219 
lack of resources and time to educate all staff about each patient’s circumstances. MAR 220 
(medication administration record) charts play a crucial role in the care home delivery of 221 
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medication to their patients (Alldred et al., 2009). It is a possible suggestion to maintain the 222 
rigorous use of MAR charts but incorporate them into provision of original packs and not 223 
MCAs which currently has good responses in terms of adherence from rural practices. 224 
Documentation and education are advised to be of higher value to safe handling of 225 
medication than use of an MCA (Oboh, 2011). 226 
 227 
For those patients without a carer, the use of an MCA can restore a sense of control to their 228 
lives as adherence does not only require physical capability but also a behavioural 229 
motivation. From research, patients would ideally want these aspects in a compliance aid: 230 
 Accessibility – matchbox style, reference panels, foam inserts for release 231 
 Reminder element – display of current week of regime, physical or audible cue 232 
 Transportable – to accommodate for their own lifestyle 233 
 Design – accounted for physical, sensory and cognitive issues faced by older 234 
patients 235 
 236 
Furthermore, reasons for non-adherence should be understood carefully as intentional non-237 
adherence will mean a compliance aid is ineffective. 238 
 239 
There have been developments in enhancing total medication management through the 240 
Biodose® system which looks to be promising for the future of MCAs. It contains 28 sealable 241 
and removable pods with a MAR chart and patient information. These features are targeted 242 
for care home staff and it can cater for liquid as well as oral medications. Other 243 
characteristics of Biodose® include:  244 
 pictures of the medication; 245 
 highly accurate and specific measurement devices where liquids are titrated based 246 
on their viscosities; 247 
 no need for cups and less time wastage; 248 
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 each pod has patient and medicine information; 249 
 tamper evident, but medicines are still easily accessed by arthritic patients; 250 
 cannot be resealed, thus ensuring security, safety and accountability; and 251 
 claims to improve adherence. 252 
 253 
Future Considerations on MCAs 254 
Future research into adherence aids for older individuals should consider the opinions of 255 
GPs through surveys and interviews, as well as social care workers. It would be valuable to 256 
consult older individuals to identify what they would desire in an adherence aid and how they 257 
evaluate current devices available. A usability test could be developed to compare 258 
adherence aids, with consideration given to their ease of opening, transportability and 259 
display features.  Another aspect of adherence aids which is still quite unclear is the stability 260 
of medicines once removed from original containers. Stability of medicines in MCAs should 261 
be researched in more depth. Future research should assist with the development of MCAs 262 
that are both aesthetically agreeable and account for the physical impairments of older 263 
patients. This will require active research and the collaboration of GPs, patients, pharmacists 264 
and carers. 265 
 266 
Conclusion 267 
Due to the large variety of adherence aids available, it is difficult to select one device to suit 268 
all individuals or for the one individual. Further research is required into patient medicine 269 
adherence before MCAs are widely used, particularly concerning older populations. When 270 
considering an older individual’s medication regimen, their GP, the carer, and the pharmacist 271 
are important individuals to consider in all decision making.  272 
 273 
What was clear from the research concerning MCAs is the need for a thorough and patient-274 
centred assessment tool for pharmacists to use when choosing whether MCAs are 275 
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appropriate for their patient. A tool should be developed to assist with determining if non-276 
adherence is intentional or unintentional. If unintentional, it should be proceed to utilise 277 
reminders and methods to easily access their medication. The MCA chosen must be tailored 278 
towards the patient considering factors such as accessibility, function as a medication 279 
storage container and convenience for the patient or person responsible for administering 280 
medication. 281 
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